Skip to main content

Table 1 Baseline characteristic of 686 patients receiving NVP-based HAART.

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Baseline characteristics Not receiving fluconazole Receiving fluconazole Pvalue
  (n = 225) 400 mg/week (n = 392) 200 mg/day (n = 69)  
Gender: Male 116 (51.6%) 213 (54.3%) 49 (71.0%) 0.016
Female 109 (48.4%) 179 (45.7%) 20 (29.0%)  
Age, years, mean ± SD 36.0 ± 7.5 35.0 ± 7.4 34.7 ± 8.03 0.200
Weight, kg., mean ± SD 54.9 ± 10.6 52.3 ± 10.0 51.4 ± 8.7 0.008
Previous opportunistic infections, patients (%)     
Any major opportunistic infections 53 (23.6%) 120 (30.6%) 24 (34.8%) 0.368
Tuberculosis 32 (14.2%) 64 (16.3%) 17 (24.6%) 0.124
PCP 31 (13.8%) 47 (12.0%) 8 (11.6%) 0.787
Histoplasmosis 3 (1.3%) 1 (0.3%) - 0.190
Penicilliosis 3 (1.3%) 0 (0.0%) - 0.046
Toxoplasmosis - 5 (1.3%) - 0.151
MAC 2 (0.9%) 2 (0.5%) - 0.669
Concurrent medication     
Cotrimoxazole 176 (78.2%) 363 (93.3%) 57 (82.6%) < 0.001
Antituberculous drugs 47 (20.9%) 82 (20.9%) 22 (31.9%) 0.095
Baseline CD4 cell count, cell/mm3, median (IQR) 85 (21–159) 18 (7–48) 16 (5–35) < 0.001
Baseline % CD4, median (IQR) 7 (2–11) 2 (1–5) 2 (1–5) < 0.001
Baseline plasma HIV RNA, 207,500 270,000 169,000 0.095
copies/ml, median (IQR) (68,375–549,500) (118,000–545,000) (76,750–415,000)  
Baseline AST, U/L, median (IQR) 31 (23–46.5) 32 (25–53.2) 34 (24–53) 0.358
Baseline ALT, U/L, median (IQR) 23 (17–39) 28 (17–45) 32 (17–49.5) 0.177
Baseline TB, mg/dl, median (IQR) 0.5 (0.4–0.65) 0.5 (0.4–0.7) 0.5 (0.4–0.8) 0.843